ANI acquires approved ANDA for Flecainide Acetate tablets USP ANI Pharmaceuticals.

Przybyl, President and CEO of ANI Pharmaceuticals, stated, ‘This acquisition additional expands our near-term generic pipeline. We intend to re-launch the item next 12 months. We are excited that this transaction further extends the ANI-Teva romantic relationship.’ ANI provides forty-seven generic medication products under advancement addressing a total annual marketplace size of approximately $3.0 billion, predicated on data from IMS Health.. ANI acquires approved ANDA for Flecainide Acetate tablets USP ANI Pharmaceuticals, Inc. today announced that it has obtained the approved abbreviated brand-new drug software for Flecainide Acetate tablets USP 50mg, 100mg and 150mg, marketed by Teva Pharmaceuticals previously.Kent Yucel, MD, FACR, chair of the ACR Committee on Diagnostic Interventional and Imaging Radiology Appropriateness Criteria.. AHA/ASA identify top cardiovascular and stroke analysis advances for 2012 Resuscitation, cell regeneration, a new high blood circulation pressure treatment and developments in products for treating stroke are among the main element scientific findings that make up this year's best cardiovascular and stroke analysis identified by the American Center Association and American Stroke Association.D., president of the American Heart Association.